Cerulean Pharma Cmn (NASDAQ:CERU) shares traded -29.2% down during most recent session to reach at the closing price of $0.8. The stock exchanged hands 20.31 Million shares versus average trading capacity of 1.21 Million shares, yielding a market cap of $23.6 Million. Wall Street analysts covering the stock are projecting that the stock will reach $3.75 within the next 52-weeks. The mean target projections are based on 2 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Cerulean Pharma Cmn (NASDAQ:CERU) high price target of $6 and with a conservative view have low price target of $1.5.

Barclays “Maintained” Cerulean Pharma Cmn (NASDAQ:CERU) in a research note issued to investors on 8/30/16 to Overweight with price target of $2.

Additionally on 8/18/16 Leerink Swann “Downgrades” Cerulean Pharma Cmn (NASDAQ:CERU) to Market Perform setting price target at $ and on 8/18/16 Janney Capital “Downgrades” the stock to Neutral. Furthermore on 8/18/16 Wedbush “Downgrades” the stock to Neutral at $1.

On the other hand the company has Relative Strength Index (RSI 14) of 64.55 along with Average True Range (ATR 14) of 0.12, Consequently Cerulean Pharma Cmn (NASDAQ:CERU)’s weekly and monthly volatility is 48.34%, 19.44% respectively. The company’s beta value is at 0.

In terms of Buy, Sell or Hold recommendations, Cerulean Pharma Cmn (NASDAQ:CERU) has analysts’ mean recommendation of 1. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

Previously Cerulean Pharma Cmn (NASDAQ:CERU) reported $-0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.31 by $0.04. The company posted an earnings surprise of 12.9%.

Currently Cerulean Pharma Cmn (NASDAQ:CERU)’s shares owned by insiders are 1.3%, whereas shares owned by institutional owners are 31.5%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 11.94%.

Cerulean Pharma Cmn (NASDAQ:CERU) 52-week high price stands at $3.58 and low price stands at $0.32, its price distance from 52-week high is -77.65% while its distance from 52-week low price is 147.68%. The stock hit its 52-week high on 03/17/17, and 52-week low on 06/20/17.

Cerulean Pharma Cmn (NASDAQ:CERU)’s trailing twelve month revenues are $2 Million, whereas its price to sales ratio for the same period is 11.8. Its book value per share for the most recent quarter is $0.27 while its price to book ratio for the same period is 2.96, as for as the company’s cash per share for the most recent quarter is $0.41, however its price to cash per share ratio for the same period is 1.97. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.